Rilzabrutinib could be effective treatment option in individuals with moderate to severe chronic spontaneous urticaria: JAMA Jacinthlyn Sylvia30 April 2025 8:15 PM ISTA new study published in the Journal of American Medical Association showed that Rilzabrutinib decreased itching and hives while preserving a positive...
USFDA grants orphan drug designation to Sanofi Rilzabrutinib for two rare diseases Ruchika Sharma3 April 2025 2:45 PM ISTParis: Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to Rilzabrutinib, an...
Rilzabrutinib therapy in pemphigus patients shows effective outcomes in phase 2 trial Jacinthlyn Sylvia11 April 2024 8:00 AM ISTA recent phase 2 clinical trial found positive outcomes in patients with pemphigus a rare and potentially life-threatening autoimmune disease. The...
Rilzabrutinib effective and safe against chronic spontaneous urticaria, finds study Jacinthlyn Sylvia1 March 2024 12:15 AM ISTA recent study published in the Journal of Allergy and Clinical Immunology unveiled promising results from a Phase 2 study evaluating the efficacy and...
Oral rilzabrutinib, first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: phase II BELIEVE study Dr Manoj Kumar Nayak15 Sept 2022 10:00 AM ISTOral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study Pemphigus vulgaris (PV) is a...
Rilzabrutinib shows promise for immune thrombocytopenia in phase 1-2 trial: NEJM Dr. Kamal Kant Kohli18 April 2022 10:15 AM ISTBOSTON: In people with immune thrombocytopenia (ITP), the body produces destructive antibodies against platelets in the blood, which increases the...
Sanofi Rilzabrutinib phase 3 trial for Pemphigus treatment fails to meet endpoints Ruchika Sharma11 Sept 2021 4:08 PM ISTParis: In a setback to Sanofi, the Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet...
Sanofi to acquire US-based Principia for USD 3.7 billion Ruchika Sharma18 Aug 2020 1:09 PM ISTThe acquisition, announced by Sanofi and Principia gives Principia's pipeline in autoimmune diseases. They include a drug aimed at the rare but...
Sanofi studies potential acquisitions of US biotechnology companies including Principia Biopharma Ruchika Sharma19 July 2020 9:00 AM ISTChief Executive Officer Paul Hudson, who joined last year, is seeking to rejuvenate Sanofi by focusing on fast-growing areas where new medicines...
